Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. PaxMedica, Inc.
  6. Company
    PXMD   US70424C1045

PAXMEDICA, INC.

(PXMD)
SummaryNewsCompanyFinancials 
Business Summary
PaxMedica, Inc. is an early clinical stage biopharmaceutical company. The Company is focused on the development of anti-purinergic therapies (APT) for the treatment of neurodevelopmental disorders, including autism spectrum disorder (ASD) and Fragile X syndrome tremor-ataxia (FXTAS). Its pipeline includes PAX-101 and PAX-102. It is focused on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD, FXTAS and Human African Trypanosomiasis (HAT). Its lead neurodevelopmental indication for PAX-101 is ASD. PAX-102, an intranasal formulation of suramin, is also being developed for neurodevelopmental indications.
Managers
Name Title Age Since
Joseph Lucchese Chief Financial Officer 54 2020
Zachary Rome Chief Operating Officer & Director 37 2019
Karen Dawes Independent Director 69 2020
Paul Kevin Wotton, Dr. Independent Director 60 2020
Robert F. Apple Independent Director 55 2020
Members of the board
Name Title Age Since
Zachary Rome Chief Operating Officer & Director 37 2019
Karen Dawes Independent Director 69 2020
Paul Kevin Wotton, Dr. Independent Director 60 2020
Robert F. Apple Independent Director 55 2020
Brand Portfolio
In partnership withAllbrands.markets
More brands of PaxMedica, Inc.